Quantcast

Latest Advaxis Stories

2014-07-02 08:26:23

KANSAS CITY, Kan., July 2, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it has filed for a product license from the United States Department of Agriculture (USDA) for AT-014, a novel her2/neu-directed cancer immunotherapy licensed exclusively from Advaxis, Inc. (NASDAQ: ADXS) for the...

2014-06-11 08:30:52

Inovio Responds to False and Misleading Speculation Regarding Immunotherapy Study BLUE BELL, Pa., June 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) wishes to clarify that a third party article published on June 10, 2014, was misrepresentative of facts and can only be taken as malicious. The referenced article does not reflect the progress, status, and potential of Inovio's active immune therapy technology and products and is rife with false and misleading...

2014-05-29 12:29:19

PRINCETON, N.J., May 29, 2014 /PRNewswire/ -- inVentiv Health Clinical, a leading global clinical research organization (CRO), and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing cancer immunotherapies, announced today that they have entered into a global master services agreement for the clinical development of certain immunotherapy product candidates in Advaxis's proprietary pipeline. inVentiv initially will work with Advaxis to develop clinical study protocols and will...

2014-04-30 16:29:50

Grant Earmarked for Trial Drug Aimed at Treatment of Anal Cancer LOS ANGELES, April 30, 2014 /PRNewswire/ -- The Farrah Fawcett Foundation (FFF) has presented a $50,000 grant to the Brown University Oncology Research Group (BrUOG) for "BrUOG 276: A Phase II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer," it was announced by Alana Stewart, President of The FFF. The grant will allow for the continued coordination and management of this novel...

2014-04-23 12:30:36

LONDON, April 23, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Human papillomavirus (HPV) Associated Cancer Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/drug_discovery/human_papillomavirus_hpv_associated_cancer_global_clinical_trials_review_h1_2014.html Human papillomavirus (HPV) Associated Cancer Global Clinical Trials Review, H1, 2014 SummaryGlobalData's clinical trial report, "Human papillomavirus (HPV)...

2014-03-19 20:21:22

-- Collaboration Focused on Cancer Immunotherapies for Pets -- KANSAS CITY, Kan., and PRINCETON, N.J., March 19, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global...

2014-02-28 16:23:52

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Advaxis, Inc. NEW YORK, Feb. 28, 2014 /PRNewswire/ -- Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Advaxis, Inc. ("Advaxis" or the "Company") (NasdaqCM: ADXS) for potential breaches of fiduciary duties in connection with their...

2014-02-11 08:33:33

AMSTERDAM, February 11, 2014 /PRNewswire/ -- - SynCo's live microbial track record, GMP scale-up and commercial manufacturing capabilities will facilitate the advancement of Advaxis' ADXS-HPV program - SynCo Bio Partners B.V. [http://www.syncobiopartners.com ], a leading services provider for GMP manufacturing of live microbial vaccines and biotherapeutics today announces that they have entered into a long term manufacturing collaboration with Advaxis, Inc....

2014-02-11 04:22:13

NORTH BRUNSWICK, N.J., Feb. 11, 2014 /PRNewswire/ -- PDS Biotechnology Corp., a clinical-stage biotechnology company focused on the development of novel immunotherapy treatments for cancer and other chronic diseases, as well as novel preventive vaccines, today announced that the first patient has been successfully vaccinated with PDS0101 in a Phase 1 clinical trial in patients with cervical intraepithelial neoplasia. The trial which is being conducted at three leading gynecological...

2013-12-05 23:04:13

Reportbuyer.com just published a new market research report: Cancer Vaccine Partnering Agreements. London (PRWEB) December 05, 2013 The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in cancer vaccine partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer vaccine partnering contract...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.